In the future, we will examine in all women recruited in the Diana-5 study how IGF-1 levels, insulin resistance, and fasting insulin levels in women without MetS may influence the incidence of relapses, secondary BC, and metastases compared to women diagnosed with MetS. This evidence concerns the gene IGF1 and breast cancer.